For example, in clinical trials of semaglutide 2.4 mg (Wegovy), nausea occurred in approximately 44% of patients, while rates for tirzepatide and other GLP-1s vary: Nausea : Often described as mild queasiness, particularly after eating, though some patients experience more pronounced nausea Bloating and abdominal fullness : A sensation of delayed digestion or food sitting heavily in the stomach Changes in bowel habits : Constipation affects approximately 15-30% of patients (varying by medication and dose), while some experience diarrhea or alternating patterns [1] [4] Decreased appetite : Beyond simple fullness, many report a fundamental shift in food thoughts, with reduced cravings and less mental preoccupation with eating Some patients report fatigue or low energy , particularly during the initial weeks
The delivery method you use determines how efficiently BPC-157 reaches the tissues that need it most
Musculoskeletal Applications Musculoskeletal applications of GLP-1 RAs gained substantial momentum in 20242025, particularly for the management of osteoarthritis and sarcopenia, with systematic reviews identifying consistent signals supporting favorable structural, protective, immunomodulatory, and analgesic effects [166]
But he was not very happy about me going on a GLP-1
